Torrent Sees Fortunes Affected By Regulatory Overhang
Dahej Unit Heads For Re-inspection By Mid-2020
Torrent has tempered FY21 US growth expectations while it plans to put Dahej, Indrad and Levittown plants up for FDA inspection in 2020. Meanwhile, products launched in India, including remoglifozin in-licensed from Glenmark, have shown an encouraging uptake.
You may also be interested in...
Aczone Generic Approval In Sight, All Clear At Sites Key To Torrent’s US Outlook
Torrent expects US FDA’s final approval for Allergan/Almirall’s Aczone, a dapsone formulation for acne vulgaris, in February, even as it awaits regulatory clearance for manufacturing sites. Meanwhile, it has launched molnupiravir in India and is hiking its domestic sales force by 400-500.
As US Slows Down, Torrent Aims For Germany, Brazil
A lack of new launches and price erosion caused a sharp dip in Torrent’s Q3 US revenues, but the company plans to ramp up its presence in Brazil and Germany to build momentum. Meanwhile, the field force in India has been downsized with an aim to defocus on older brands.
Torrent Outlook Muted On COVID-19
After a tepid performance in the fiscal fourth quarter, Torrent expects its key markets India, US and Brazil to be impacted by the COVID-19 fallout as well as a lack of visibility on regulatory approvals for its manufacturing facilities.